CKD-712 是一种口服有效的多靶点四氢异喹啉衍生物,也是 NF-κB 通路的强效抑制剂,它可选择性抑制 MMP-9 而对 MMP-2 无作用,还能下调 TNF-α、IL-6、cyclin A、cyclin B、CDK-1 等蛋白的表达并激活 PI3K/Akt 信号通路,通过阻断 NF-κB 的激活与核转位、下调炎症因子及促肿瘤转移蛋白、诱导肿瘤细胞发生 G2/M 期阻滞,进而抑制癌细胞侵袭,可用于脓毒症、心肌缺血再灌注损伤及非小细胞肺癌的相关研究。
产品编号: MS-B29015 CAS No.: 626252-75-3 分子式: C20H19NO2 分子量: 305.37
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

CKD-712 是一种口服有效的多靶点四氢异喹啉衍生物,也是 NF-κB 通路的强效抑制剂,它可选择性抑制 MMP-9 而对 MMP-2 无作用,还能下调 TNF-α、IL-6、cyclin A、cyclin B、CDK-1 等蛋白的表达并激活 PI3K/Akt 信号通路,通过阻断 NF-κB 的激活与核转位、下调炎症因子及促肿瘤转移蛋白、诱导肿瘤细胞发生 G2/M 期阻滞,进而抑制癌细胞侵袭,可用于脓毒症、心肌缺血再灌注损伤及非小细胞肺癌的相关研究。

生物实验数据

生物活性 CKD-712 is an orally effective multi-target tetrahydroisoquinoline derivative and a potent inhibitor of the NF-κB pathway that selectively inhibits MMP-9 without affecting MMP-2, downregulates the expression of proteins such as TNF-α, IL-6, cyclin A, cyclin B, and CDK-1, and activates the PI3K/Akt signaling pathway; by blocking NF-κB activation and nuclear translocation, downregulating inflammatory factors and pro-metastatic proteins, and inducing G2/M phase arrest in tumor cells, it inhibits cancer cell invasion, and can be used for research on sepsis, myocardial ischemia-reperfusion injury, and non-small cell lung cancer.
IC50 & Target

NF-κB

 

MMP-9

 

IL-6

 

Cdk1/cyclin B

 

CDK1/cyclin A

 

PI3K

 

Akt

 

体外研究
(In Vitro)

CKD-712 (5-30 μg/mL; 48 h) 可剂量依赖性地抑制人肺腺癌细胞 A549 的增殖,其中 30 μg/mL 可使增殖抑制率达到 60%,且不会诱导细胞死亡。
CKD-712 (30-50 µg/ml; 48 h) 可诱导 A549 细胞发生 G2/M 期细胞周期停滞。
CKD-712 (30 µg/ml; 48 h) 可抑制人肺癌 A549 细胞中细胞周期蛋白 A、细胞周期蛋白 B 及 CDK-1 的表达。
CKD-712 (30 µg/ml; 48 h) 可剂量依赖性地抑制人肺癌 A549 细胞的有丝分裂。
CKD-712 (20 µg/ml; 12 h, 24 h) 可抑制腺癌细胞的生长。
CKD-712 (10 µg/ml; 1 h; 预孵育) 可抑制 TNF-α 诱导的人肺癌 A549 细胞中 NF-κB 的活化。
CKD-712 (5-30 µg/ml; 24 h) 可抑制人肺癌 A549 细胞中参与增殖、抗凋亡及血管生成的相关蛋白的表达。
CKD-712 (30 µg/ml; 48 h) 可剂量依赖性地抑制人肺癌 A549 细胞中 MMP-9 的活性,且不影响 MMP-2 的活性。

Cell Proliferation Assay

Cell Line: A549 human lung carcinoma cells
Concentration: 5 μg/mL, 10 μg/mL, 20 μg/mL, 30 μg/mL
Incubation Time: 48 h
Result: Significantly suppressed cell proliferation in a dose-dependent manner up to 60% at 30 μg/mL.

Western Blot Analysis

Cell Line: A549 human lung carcinoma cells
Concentration: 5 μg/mL, 10 μg/mL, 20 μg/mL, 30 μg/mL
Incubation Time: 48 h
Result: Suppressed the expression of cyclin A, cyclin B and CDK-1 proteins.

Western Blot Analysis

Cell Line: A549 human lung carcinoma cells
Concentration: 5 μg/mL, 10 μg/mL, 20 μg/mL, 30 μg/mL
Incubation Time: 24 h
Result: Inhibited TNF-α-induced NF-κB p65 nuclear translocation; suppressed proteins involved in proliferation, anti-apoptosis, and angiogenesis including Mcl-1, COX-2, XIAP, and VEGF in A549 cells.

Cell Invasion Assay

Cell Line: A549 human lung carcinoma cells
Concentration: 5 μg/mL, 10 μg/mL, 20 μg/mL, 30 μg/mL
Incubation Time: 24 h
Result: Inhibited A549 cell invasion in a dose-dependent manner.

Cell Migration Assay

Cell Line: A549 human lung carcinoma cells
Concentration: 20 μg/mL
Incubation Time: 12 h, 24 h
Result: Inhibited A549 cell migration as evidenced by controlled wound closure compared to test.

Cell Cycle Analysis

Cell Line: A549 human lung carcinoma cells
Concentration: 5 μg/mL, 10 μg/mL, 20 μg/mL, 30 μg/mL
Incubation Time: 48 h
Result: Induced marked cell cycle changes with an increase in the fraction of cells in G2/M, indicating significant G2/M cell death.
体内研究
(In Vivo)

CKD-712 (1-20 mg/kg; 腹腔注射;单次给药;LPS 前 30 分钟) 可剂量依赖性地预防小鼠中 LPS 诱导的低体温症,在 LPS 攻击后 5 和 7 小时维持显著更高的体温。
CKD-712 (1-3 mg/kg/ 天;腹腔注射;每日一次;共 4 次给药) 可提升 CLP 诱导的多微生物败血症小鼠的存活率,在以 1 mg/kg/ 天的剂量给药 4 天的情况下,观察到 50% 的存活率。
CKD-712 (2.5-20 mg/kg; 腹腔注射;两次给药 (间隔 24 小时,LPS 前 1 小时)) 可剂量依赖性地降低 LPS 诱导的 DIC 大鼠的肝、肾损伤标志物水平,在 20 mg/kg 剂量下,GOT (117.8 U/L) 和 BUN (11.8 mg/dL) 的降低幅度最大。
CKD-712 (20 mg/kg; 腹腔注射;两次给药 (间隔 24 小时,LPS 前 1 小时)) 可保护 DIC 大鼠免受 LPS 诱导的肝肺组织学损伤,减少炎症细胞浸润和组织坏死。
CKD-712 (1-20 mg/kg; 腹腔注射;单次给药) 可剂量依赖性地改善 LPS 诱导的脓毒症小鼠的存活率;在 LPS 处理前 30 分钟给药时,5 mg/kg 和 10 mg/kg 剂量组的存活率最高可达 92%。
CKD-712 (5-20 mg/kg; 腹腔注射;单次给药;酵母聚糖前 30 分钟) 可提高酵母聚糖诱导的脓毒症小鼠的存活率,在提前 30 分钟给药的 20 mg/kg 剂量下,观察到的存活率为 67%。
CKD-712 (2.5-20 mg/kg; 腹腔注射;两次给药 (间隔 24 小时,LPS 前 1 小时)) 可剂量依赖性地抑制 LPS 诱导的弥散性血管内凝血 (DIC) 大鼠的全身性炎症反应,在 10 mg/kg 剂量下对 TNF-α 的抑制作用最强 (降至 85.5 pg/mL)。
CKD-712 (20 mg/kg; 腹腔注射;两次给药 (间隔 24 小时,LPS 前 1 小时)) 可抑制 LPS 诱导的 DIC 大鼠肺细胞中 NF-κB 向细胞核的转位,从而减少促炎信号传导。

Animal Model: ICR (male, 25-30 g, zymosan-induced endotoxemia sepsis model)
Dosage: 5, 10, 20 mg/kg
Administration: Intraperitoneal (i.p.) single dose; 30 min pre-zymosan
Result: Achieved survival rates of 42%, 50%, and 67% at 5, 10, and 20 mg/kg respectively at 6 days post-zymosan (statistically significant at 20 mg/kg, p ≤ 0.05).
Animal Model: ICR (male, 25-30 g, LPS-induced hypothermia sepsis model)
Dosage: 1, 3, 10, 20 mg/kg
Administration: Intraperitoneal (i.p.) single dose; 30 min pre-LPS
Result: Prevented LPS-induced hypothermia, maintaining significantly higher mean rectal temperatures compared to vehicle controls at 5 and 7 hours post-LPS (p ≤ 0.05).
Enabled all groups to recover to normal temperatures by 23 hours post-LPS.
Animal Model: ICR (male, 25-30 g, CLP-induced polymicrobial sepsis model)
Dosage: 1, 3 mg/kg/day
Administration: Intraperitoneal (i.p.) once daily; 4 total doses (2 pre-surgery, 2 post-surgery)
Result: Improved final survival rates to 50% and 45% at 1 mg/kg/day and 3 mg/kg/day respectively, compared to 15% survival with CLP alone at 72 hours post-surgery.
Sprague-Dawley (SD) (male, 150–160 g, LPS-induced systemic inflammation Dlc model)
Animal Model: ICR (male, 25-30 g, LPS-induced endotoxemia sepsis model)
Dosage: 1, 3, 10, 20 mg/kg (4 hours post-LPS)
Administration: Intraperitoneal (i.p.) single dose
Result: Achieved survival rates of 33%, 40%, 40%, and 53% at 1, 3, 10, and 20 mg/kg respectively when administered 4 hours post-LPS.
Animal Model: ICR (male, 25-30 g, LPS-induced endotoxemia sepsis model)
Dosage: 2.5, 5, 10, 20 mg/kg (1 hour post-LPS)
Administration: Intraperitoneal (i.p.) single dose
Result: Achieved survival rates of 47%, 60%, 67%, and 67% at 1, 3, 10, and 20 mg/kg respectively when administered 1 hour post-LPS (statistically significant at 10, 20 mg/kg, p ≤ 0.05).
Animal Model: Sprague-Dawley (SD) (male, 150-160 g, LPS-induced septic organ injury Dlc model)
Dosage: 20 mg/kg
Administration: Intraperitoneal (i.p.); two doses (24 hours and 1 hour pre-LPS)
Result: Inhibited LPS-induced translocation of NF-κB from the cytoplasm to the nucleus of lung pneumocytes, with NF-κB remaining localized to the cytoplasm.
Reduced liver sinusoidal enlargement and inflammatory cell infiltration caused by LPS.
Reduced lung pneumocyte hypertrophy, inflammatory cell infiltration, and central necrosis caused by LPS.
Animal Model: Sprague-Dawley (SD) (male, 150–160 g, LPS-induced systemic inflammation Dlc model)
Dosage: 2.5, 5, 10, 20 mg/kg
Administration: Intraperitoneal (i.p.); two doses (24 hours and 1 hour pre-LPS)
Result: LPS-induced GOT, GPT, BUN, creatinine, TNF-α, and IL-6 levels were all reduced in a dose-dependent manner at 2.5, 5, 10, and 20 mg/kg respectively.

化学信息

分子量 305.37
分子式 C20H19NO2
CAS No. 626252-75-3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础